English
Spanish
French
German
Italian
Chinese (Simplified)
Japanese
Korean
Arabic
Portuguese
OptiBio Co., Ltd. is a South Korean in-
Optical Q Fluorescence Immunoassay Diagnostic Device
Product Details:
X
Optical Q Fluorescence Immunoassay Diagnostic Device Price And Quantity
- 1 Unit
Product Description
Product Description
Product Features
Optical Q is a cutting edge in-vitro diagnostics fluorescence immunoassay analyzer (FIA) that accurately measures the concentration of analytes contained in blood, serum, plasma, and other samples. Results are generated within a prompt 15-minute time frame with CV's ranging from 5%, 10%.
Performance
- Instant results within 3, 15 minutes / High CV performance <10% / 27 test parameters and expanding
Convenience
- 3 step process: dilute, drop, analyze / Portable weight and size / Modifiable tests
Technology
- Top optical lens resolution F/N 1 / RFID for test and lot identification / Internal printer for results
Specification
Product Usage
In contrast to standard FIA analyzers that use gold nano-particles, Optical Q utilizes advanced fluorescence chemistry and incorporates world class lens technology to more accurately quantify the concentration or severity of each analyte. In addition, Optical Q features a wide variety of diagnostic markers many of which are developed in house that covers health categories including but not limited to inflammation, infection, diabetes, vitamin D deficiency, thyroids, and more. Our capacity to develop our device and antibodies in-house enables optimized performance against competitors, continued expansion of our test menu, and modification of tests based on client needs. From private physician offices to larger hospital laboratories and emergency departments, Optical Q high performance, objectivity, and quality control make Optical Q the perfect solution for those looking to improve their rapid testing algorithm. Optical Q is truly a rapid one stop diagnostic solution
Company Profile
vitro diagnostics (IVD) company focused
in researching, developing, and
manufacturing cutting edge fluorescence
immunoassay (FIA) solutions to enhance
and progress quality healthcare access
globally. In 2020, OptiBio was selected by
a research fund sponsored by the Bill &
Melinda Gates foundation for its unique
and dedicated approach to immunoassay.
OptiBio's fundamental approach of
integrating in-house capabilities allows
OptiBio to constantly improve its product
performance, customize its solutions
based on client feedback, develop new
test parameters, and respond to changing
market needs. OptiBio will continue to
create, improve, and innovate world class
diagnostic solutions in the field of
fluorescence immunoassay and point-of-
care testing (POCT). Through this, we aim
to ultimately transform medical diagnosis
into a universally available right.
Enter Buying Requirement Details
Send Inquiry
